These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 33798836)
1. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study. Ibrahim MAA; Mohamed EAR; Abdelrahman AHM; Allemailem KS; Moustafa MF; Shawky AM; Mahzari A; Hakami AR; Abdeljawaad KAA; Atia MAM J Mol Graph Model; 2021 Jun; 105():107904. PubMed ID: 33798836 [TBL] [Abstract][Full Text] [Related]
2. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249 [TBL] [Abstract][Full Text] [Related]
3. Natural-like products as potential SARS-CoV-2 M Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Hegazy MF J Biomol Struct Dyn; 2021 Sep; 39(15):5722-5734. PubMed ID: 32643529 [TBL] [Abstract][Full Text] [Related]
4. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M Ibrahim MAA; Abdelrahman AHM; Mohamed TA; Atia MAM; Al-Hammady MAM; Abdeljawaad KAA; Elkady EM; Moustafa MF; Alrumaihi F; Allemailem KS; El-Seedi HR; Paré PW; Efferth T; Hegazy MF Molecules; 2021 Apr; 26(7):. PubMed ID: 33916461 [TBL] [Abstract][Full Text] [Related]
5. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease. Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340 [TBL] [Abstract][Full Text] [Related]
6. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388 [TBL] [Abstract][Full Text] [Related]
12. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M Purohit P; Dash JJ; Muya JT; Meher BR J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744 [TBL] [Abstract][Full Text] [Related]
13. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
14. GC-MS profiling of Bauhinia variegata major phytoconstituents with computational identification of potential lead inhibitors of SARS-CoV-2 M More-Adate P; Lokhande KB; Swamy KV; Nagar S; Baheti A Comput Biol Med; 2022 Aug; 147():105679. PubMed ID: 35667152 [TBL] [Abstract][Full Text] [Related]
15. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents. Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129 [TBL] [Abstract][Full Text] [Related]
16. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. Ancy I; Sivanandam M; Kumaradhas P J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689 [TBL] [Abstract][Full Text] [Related]